Sponsor:
NewAmsterdam Pharma
Code:
NCT06305559
Conditions
Lipidemia
Coronary Artery Disease
Plaque, Atherosclerotic
Eligibility Criteria
Sex: All
Age: 45+
Healthy Volunteers: Not accepted
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Placebo
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by NewAmsterdam Pharma on 2024-11-14.